PureTech Health — Full Portfolio
6 tracked investments · listed companies and verified rows first
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)
BoardJames I. Healy(Director)
Co-investorsARCH Venture PartnersForesite CapitalHAWKTAILSofinnova Ventures
Celea is a biopharmaceutical company developing next-generation therapies for serious respiratory diseases, with a lead antifibrotic drug candidate, deupirfenidone, in Phase 3 development for idiopathic pulmonary fibrosis (IPF).
BiotechMedical Devices
Co-investorsRA CapitalLeaps by Bayer
PureTech-founded entity advancing deupirfenidone (via the Phase 3 SURPASS-IPF trial) as a potential new standard of care for idiopathic pulmonary fibrosis.
PureTech Founded Entity that developed KarXT (Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14 billion.
Co-investorsSofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.